BPC-157 (in IBD clinical trials as PL14736) also improved healing of various healing-impaired wounds in rats, extending its clinical utility from GI inflammation to complex wound healing applications.
Key findingBPC-157 (PL14736, in IBD clinical trials) effectively healed various types of healing-impaired wounds in rats including steroid-impaired, denervated,
What the researchers found
BPC-157 (PL14736, in IBD clinical trials) effectively healed various types of healing-impaired wounds in rats including steroid-impaired, denervated, and complex soft tissue injuries — expanding its clinical development potential from IBD to wound healing indications.
Why it matters
Relevant for bpc-157, gut-healing, wound-healing.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.
Journal of pharmacological sciences, 108(1), 7-17
Citation
Klicek, Robert; Sever, Marko; Radic, Bozo; Drmic, Domagoj; Kocman, Ivan; Zoricic, Ivan; Vuksic, Tihomir; Ivica, Mihovil; Barisic, Ivan; Ilic, Spomenko; Berkopic, Lidija; Vrcic, Hrvoje; Brcic, Luka; Blagaic, Alenka Boban; Coric, Marijana; Brcic, Iva; Rokotov, Dinko Stancic; Anic, Tomislav; Seiwerth, Sven; Sikiric, Predrag. (2008). Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system.. Journal of pharmacological sciences, 108(1), 7-17.